Vanguard Group Inc. Purchases 311,082 Shares of Codexis, Inc. (NASDAQ:CDXS)

Vanguard Group Inc. boosted its position in Codexis, Inc. (NASDAQ:CDXS) by 7.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,463,801 shares of the biotechnology company’s stock after purchasing an additional 311,082 shares during the quarter. Vanguard Group Inc. owned approximately 5.49% of Codexis worth $21,292,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Kingswood Wealth Advisors LLC bought a new position in Codexis during the 4th quarter valued at approximately $79,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Codexis in the fourth quarter worth $82,000. Intech Investment Management LLC grew its stake in shares of Codexis by 55.1% in the fourth quarter. Intech Investment Management LLC now owns 33,111 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 11,757 shares during the last quarter. Jackson Square Capital LLC purchased a new position in shares of Codexis in the 4th quarter worth about $210,000. Finally, Monimus Capital Management LP purchased a new position in shares of Codexis in the 4th quarter worth about $339,000. Hedge funds and other institutional investors own 78.54% of the company’s stock.

Codexis Stock Performance

Shares of CDXS stock opened at $2.25 on Wednesday. The company has a market capitalization of $186.38 million, a price-to-earnings ratio of -2.59 and a beta of 2.35. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. Codexis, Inc. has a one year low of $1.90 and a one year high of $6.08. The company’s 50-day moving average is $3.06 and its 200 day moving average is $3.87.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.09). The firm had revenue of $21.46 million for the quarter, compared to the consensus estimate of $27.41 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. Sell-side analysts expect that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.